Social media

On 30 March - 2 April at World Vaccine Congress, meet ICON experts at booth #222 to learn about our 30+ years of experience supporting vaccine development for biotech, pharma, government, and NGOs. https://ow.ly/GzT350Yr...

Attending the GLP-1-Based Therapeutics Summit in Boston? On 15 April at 12:00 pm, ICON’s Alan Baldridge will be presenting, “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.” He’...

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

Clinical trials are powered by people. Behind every study is a cross functional team working across countries, time zones and specialist areas to deliver safe, high quality research. From study start up and site activa...

Clinical trials are powered by people. Behind every study is a cross functional team working across countries, time zones and specialist areas to deliver safe, high quality research. From study start up and site activa...

Thank you to everyone who joined our Rare Disease Day webinar. From gene targeted therapies to accelerated approvals, the inspiring discussion highlighted how patient leadership continues to shape ultra rare disease drug...

Missed our Rare Disease Day webinar or want to rewatch the discussion? Hear real world examples of how patient led organisations are breaking barriers in ultra rare disease drug development. Watch the recording today: ht...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

Meet our Government and Public Health team at World Vaccine Congress and unlock the power of full-service clinical development and staffing with ICON Government and Public Health Solutions. As a trusted partner of glob...

Antibody-drug conjugates (ADCs) continue to reshape global oncology, yet navigating the evolving regulatory landscape remains a significant challenge. In this new BioSpectrum Asia feature, ICON’s regulatory expert, Eili...